To the full analysis
Shanghai Pharmaceuticals Holding stock: growth
601607.SSShanghai Pharmaceuticals Holding reported $42.53B in revenue for fiscal 2025, up 3% on the prior year, up 8.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
18.4%
per year from 2006 to 2025, per share 6.4%
Earnings (Annual rate)
26.2%
per year from 2006 to 2025
Free cash flow (Annual rate)
12.2%
per year from 2006 to 2025, per share 0.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 8.1% | 10.4% | 18.4% |
| Revenue per share | 2.5% | 6.9% | 6.4% |
| Earnings | 4.9% | 7.1% | 26.2% |
| Earnings per share | −0.5% | 3.7% | no data |
| Free cash flow | 0.0% | no data | 12.2% |
| Free cash flow per share | −5.2% | no data | 0.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.71B | $10.3M | $64.71M |
| 2007 | $2.09B | $9.94M | $44.49M |
| 2008 | $2.48B | $12.29M | $29.27M |
| 2009 | $2.93B | $25.99M | $87.6M |
| 2010 | $5.61B | $205.19M | $170.33M |
| 2011 | $8.23B | $306.26M | $203.79M |
| 2012 | $10.21B | $307.86M | $66.26M |
| 2013 | $11.73B | $331.96M | $10.26M |
| 2014 | $13.86B | $388.58M | $6.63M |
| 2015 | $15.82B | $431.45M | −$55.68M |
| 2016 | $18.11B | $479.34M | −$25.89M |
| 2017 | $19.62B | $527.97M | $96.21M |
| 2018 | $23.86B | $582.02M | $178.77M |
| 2019 | $27.98B | $612M | $490.27M |
| 2020 | $28.78B | $674.27M | $575.07M |
| 2021 | $32.37B | $763.84M | $141.35M |
| 2022 | $34.79B | $842.37M | $308.7M |
| 2023 | $39.03B | $565.06M | $339.06M |
| 2024 | $41.28B | $682.72M | $513.83M |
| 2025 | $42.53B | $858.48M | $574.11M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Jul 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.